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ABSTRACT
Presently, there is large interest in analysing the interactions in vitro with plasma proteins of some
novel antitumor ruthenium(Ill) complexes that are in preclinical or clinical phase. The joint application of
separation and spectroscopic techniques provides valuable information on the nature and the properties of the
resulting ruthenium/protein adducts. Recent work carried out in our laboratory points out that, under
physiological conditions, some selected ruthenium(III) complexes bind plasma proteins tightly with a marked
preference for surface imidazole groups. Representative examples of interactions of antitumor ruthenium(Ill)
complexes with plasma proteins such as albumin and transferrin are given. Notably the antitumor
ruthenium(Ill) complexes considered here bind proteins much tighter than DNA; it is proposed that protein
binding of ruthenium(Ill) complexes will have a large impact on the biodistribution, the pharmacokinetics
and the mechanism of action ofthese experimental drugs.
INTRODUCTION
The importance of metal complexes in cancer chemotherapy is best documented by the results
obtained with platinum(II) compounds; today cisplatin is one of the most used anticancer drugs against a
wide range of malignancies including testicular carcinomas, ovarian tumors, head and neck cancers, bladder
tumor and osteosarcoma [1]. Several detailed studies prove that the mechanism of action of platinum(II)
complexes relies on the formation of covalent bonds with DNA [2].
Following the success of cisplatin, several metal complexes other than platinum have been
considered over the years as possible alternatives to cisplatin [3]; in particular it was found that some
ruthenium(Ill) compounds possess interesting antitumour and antimetastatic activities [4]. The field was
pioneered by M.Clarke who synthesised and tested a variety of amminochloro ruthenium(Ill) complexes [4].
Later on, the group of Keppler prepared some new ruthenium(Ill) complexes, of general formula RuCIaL2,
that turned out to be effective against a number of tumor models [5]. In the same years, the group of Mestroni
in Trieste synthesized and characterized a large number of ruthenium(lI) and ruthenium(Ill) mixed
complexes with sulfoxide ligands [6]. Aminopolycarboxylate ruthenium(Ill) complexes designed on the basis
of RuEDTA were prepared and tested in Sevilla by the group of Gonzalez Vilchez in the following years [7].
Additional ruthenium(Ill) complexes with promising biological properties were prepared in the laboratories
of Peter Sadler [8] and Jan Reedjik [9]. As a result of such intense synthetic work, a large group
ruthenium(lII) complexes, of different structure, is now available that deserve extensive biological and
pharmacological evaluation.
When studied in vivo some representative ruthenium(Ill) complexes were found to produce
inhibition ofDNA replication, mutagenic activity, induction of the SOS repair mechanism, binding to nuclear
DNA and reduction of RNA synthesis [4]. To support a mode of action similiar to cisplatin, an "activation by
reduction" mechanism was invoked according to which the inert ruthenium(Ill) complexes would act as pro-
drugs that are activated in situ by reduction to the corresponding, more labile, ruthenium(ll) species. The
latter species is believed to be responsible of direct damage to DNA.
However, the results obtained so far point out that ruthenium(Ill) complexes bind DNA nucleobases
much weaker than platinum(ll) complexes; the conformational modifications of the double helix produced by
ruthenium(Ill) complexes are generally modest [10].
The scarce binding ability of ruthenium(Ill) complexes for DNA together with the proved affinity of
these complexes for proteins, suggests that the mechanism of action of ruthenium(Ill) complexes may be
substantially different from that of platinum complexes; other crucial biomolecules, beyond DNA, might be
the primary targets for ruthenium(Ill) compounds in cells.
Here we present experimental evidence, collected so far, documenting the favorable binding
properties of selected antitumor ruthenium(Ill) complexes for plasma proteins such as albumin and
transferrin. Among the several ruthenium(Ill) anticancer compounds prepared and tested up to now, we will
specifically consider trans-Him[RuCln(Im)2] (Im=lmidazole), ICR (figure l/A) and trans-Hlnd[RuCl4(Ind)_],
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Rulnd (from the group of B. Keppler, Heidelberg) (figure l/B) [11], Na[trans-RuCl4(Me2SO)(Im)], NAMI
(from the group of Mestroni and Alessio, Trieste) (figure l/C) [12], and dichloro-l,2-
propylendiaminetetraacetate (PDTA)Ru(III), RAP (from the group of Gonzalez Vilchez, Sevilla) (figure
l/D) [13]. This choice is dictated by the fact that the selected complexes are among the most intensely
studied ones and hold promise for future therapeutic applications. By the way we like reminding that NAMI






Figure 1: ICR (A), trans-Hind[RuCl4(Ind)2], NAMI (C) and RAP (D)
The interactions in vitro of these ruthenium(Ill) complexes with albumin and transferrin were
investigated in detail by coupling classical separation techniques with spectroscopic methods such as
spectrophotometry, circular dichroism and H NMR. Indeed, the ruthenium(Ill) chromophore is particularly
well suited for such sa pectroscopic approach since ruthenium(Ill) is paramagnetic and generally exhibits
relatively intense charge transfer transitions in the visible. The studies carried out so far provide information
on the nature and the strength of the ruthenium(III)/proteins interactions and on the possible biological
consequences of such binding.
BINDING OF RUTHENIUM(Ill) COMPLEXES TO PLASMA PROTEINS: SOME SELECTED
EXAMPLES
a) Binding ofKeppler’s compounds to the active site ofhuman serum transferrin
Keppler’s complexes, ICR and RuInd, were the first ruthenium(III) complexes whose interactions
with plasma proteins were considered in detail. Specifically, the interactions of both complexes with human
serum transferrin were investigated in solution by various techniques, including ’H NMR, HPLC,
spectrophotometry and circular dichroism [11]. These studies have shown that either ruthenium(III) complex
binds apotransferrin tightly, under physiological conditions, when working at 1:1 stoichiometry,.
Ruthenium(III) binding occurs at the level of the iron binding site but heterocyclic ligands are conserved.
Binding of ICR to apotransferrin is slow and takes place following hydrolysis of ruthenium coordinated
chlorides; binding of RuInd is much faster and is facilitated by the presence of sodium bicarbonate in
solution. Remarkably, the observation of a characteristic CD spectrum in the visible provides evidence for
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the formation of specific adducts between Keppler’s ruthenium(III) complexes and apotransferrin. Spectra
are shown in figure 2.
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Figure 2 CD spectra in the visible region showing the stepwise titration of apoTf (lxl 0-4 M) with
RuInd (A), CD spectrum in the visible region of ru-im plus apoTf (lxl0-4 M) at a 2"1 ratio, obtained after
12h incubation.
Tight binding of these ruthenium(III) complexes to apotransferrin was demonstrated by HPLC
methods; notably, it was observed that only under drastic conditions ruthenium(III) ions may be removed
from apotransferrin (citric acid 0.1 M at pH 5.5) [11]. Later on, this description of the interaction of
Keppler’s complexes with apotransferrin was confirmed by X-ray diffraction studies carried out on adducts
of apolactoferrin with Rulnd and ICR [14]. The latter studies showed that apolactoferrin can bind up to 5
ruthenium equivalents; binding takes place specifically at the iron binding sites and at exposed histidine
residues (Figure 3). Structural details of the interaction of RuInd with aminoacidic residues in the active site
of apotransferrin are shown in figure 4.
b) The reaction ofNAMI with BSA
We have recently described the reaction ofNAMI A, with bovine serum albumin (BSA hereafter)
monitored by various spectroscopic techniques [15]. We found that NAMI, following chloride hydrolysis,
binds bovine serum albumin tightly; spectrophotometric and atomic absorption data pointed out that up to 5
ruthenium equivalents are firmly bound per albumin molecule when BSA is incubated for 24 hours with an
eightfold excess of NAMI. Circular dichroism spectra showed that the various ruthenium centers bound to
albumin exhibit well distinct spectroscopic features. The first ruthenium equivalent produces a characteristic
positive CD band at 415 nm whereas the following NAMI equivalents give rise to less specific and less
marked spectral effects. At high NAMI/BSA molar ratios a broad negative CD band develops at 590 nm.
Notably the bound ruthenium centers remain in the oxidation state +3.
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Figure 3 Ribbon diagram showing of ru-im binding after soaking for 4 weeks. Sites are: (1) His 253,
(2) His 597, (3) His 590, (4) His 654.
Figure 4 Difference electron density for ru-ind in the N-terminal site of human apolactoferrin,
showing that the two indazole ligands are retained. The Ru atom binds to His 253 and the nearby side chain
of Lys 301 may help stabilize binding.





--_ .,,,:,.,,._ -,.’..’__.,,/’ ;---- ,
400 500 600 ;TOO
Figure 5 CD spectra of NAMI/BSA samples. Samples were prepared at the following NAMI/BSA
molar ratios: (a) 1:1, (b) 2:1, (c) 4:1 and (d) 8:1, and were measured after 24h incubation in buffer (phosphate
0.05M, NaCI 0.1M, pH 7.4, 25C). Protein concentration: lxl0-3M.
By analogy with the case of transferrins it was proposed that the BSA-bound ruthenium ions are
ligated to surface histidines of the protein; results from chemical modification experiments with
diethylpyrocarbonate favor this view [15]. Spectral patterns similar but not identical to those shown by
NAMI were observed when BSA was reacted with (sodium trans-bis(dimethylsulfoxide) tetrachloro
ruthenate(III)) -Na[trans RuCI4 (DMSO)2] and with (ICR), implying a similar mechanism of interaction in all
cases. Given the large abundance of albumin in the blood, it is likely that the described NAMI-BSA adducts
may form in vivo and may be relevant for the biological properties of this complex and for its sequestration;
alternatively NAMI/BSA adducts might act as specific carriers of the ruthenium complex to cancer cells.
Similar results were found by Lemieska et al. when studying the interactions of ICR and Rulnd with human
serum albumin 16,17].
c) RAP andPLASMA PROTEINS
RAP is a promising polyaminocarboxylate ruthenium(III) complex with favorable antitumor
properties. The solution behavior of RAP was characterised spectroscopically. Under physiological
conditions RAP slowly looses the two coordinated chlorine atoms to produce a number of ruthenium (III)
reactive species; the ruthenium ion always remains in the 3
+ oxidation state and the PDTA ligand is always
bound to the metal [18]. The reaction of RAP with bovine serum albumin, diferric transferrin or
apotransferrin was investigated by spectrophotometry, circular dichroism and IH NMR spectroscopy. For
these studies, buffered solutions of RAP were reacted with bovine serum albumin, diferric transferrin and
apotransferrin under a 1:1 ratio and the reaction mixtures analyzed through CD and lH NMR spectroscopies.
Surprisingly the CD spectra did not show any detectable band in the visible even after long incubation times
in contrast to the cases of Rulnd and trans-(DMSO) (Im)-tetrachlororuthenate. Instead, the IH NMR spectra
revealed significant changes of the hyperfine signals that occurred within a few minutes after mixing;
noticeably, a the same variation in the pattern of the hyperfine signals was observed when reacting RAP with
the three different samples. H NMR spectra of RAP with diferric transferrin (A), apotransferrin (B) and
albumin (C) at 25C are shown in figure 6
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Figure 6 Upfield region IH NMR spectra of RAP with diferric transferrin (a), apotransferrin (b) and
albumin (c) at 25C. Conditions: 50 nM phosphate buffer, pH 7.4; protein and RAP concentrations are in all
cases mM.
The occurrence of tight RAP-protein binding was then unambiguously demonstrated by a simple
experiment: the solution containing diferric transferrin plus one equivalent of RAP was ultrafiltered through
a Centricon with a cutoff of 10,000 daltons and the ultrafiltrate analyzed through IH NMR spectroscopy. No
H NMR hyperfine signals from RAP could be observed in the filtrate proving that most RAP (>90%)
remains tightly bound to diferric transferrin. Noticeably, protein-bound ruthenium (III) could not be
ultrafiltered even after addition of large amounts of sodium perchlorate (up to 0.5 M).
The virtual identity of the tH NMR spectra of the protein bound species in the three analyzed cases
suggests a substantially equivalent mode of binding of RAP to the three proteins. It is apparent that, in all
cases, the ruthenium ion remains in the 3
+ state and that the PDTA ligand is still bound to the metal. Given
the nearly equivalent mode of binding to the three proteins and the virtual absence of CD activity in the
visible region, it was proposed that RAP binds to amino acid side chains that are exposed to the solvent on
the protein surface. Again, a good candidate for binding is the imidazole ring of histidine which is known to
represent a favorite binding site for ruthenium (III) ions.
A GENERAL MODEL FOR THE REACTION OF ANTITUMOR RUTHENIUM(Ill) COMPLEXES
WITH PROTEINS: PHARMACOLOGICAL IMPLICATIONS AND PERSPECTIVES.
The three examples reported above provide unambiguous evidence for the formation of stable
adducts between selected antitumor ruthenium(Ill) complexes and plasma proteins. Studies carried out in our
laboratory allowed us to identify some relevant common features of the resulting adducts that are listed
below:
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1. Protein-bound ruthenium generally remains in the oxidation state +3.
2. binding is covalent and relatively tight-the ruthenium(Ill) chromophore may be displacedfrom the
protein only under drastic conditions-.
3. binding most likely occurs at the level ofhistidine residues
4. kinetics ofbinding is relatively slow; binding occurs after displacement ofruthenium-bound chlorides.
These observations emerging from spectroscopic results were nicely confirmed in the case of the
adducts of Keppler’s complexes with apolactoferrin by a single crystal X ray diffraction study. The latter
investigation unambiguously proved that stable ruthenium/proteins adducts can form in vitro. Very recently
Lobisky et al. have shown that RuInd binds human serum albumin faster and tighter than human serum
transferrin; a large amount of the ruthenium complex can be removed from albumin by treatment with EDTA
[19].
Undoubtely these results contain important pharmacological implications if one considers the
growing role of ruthenium(III) complexes as possible antitumor drugs. Usually ruthenium(III) complexes in
clinical trials are administered intravenously [20]. This implies that ruthenium(III) drugs will encounter very
soon plasma proteins, in particular serum albumin that is very abundant in the blood stream. Given the
relatively slow kinetics of protein binding, it is possible that a large amount of the ruthenium drug will escape
albumin binding and will have the chance to spread within the organism in the "free" form; in any case a
significant fraction of the injected drug will remain in the blood stream for enough time to bind plasma
proteins, in particular albumin. So detailed studies are needed to establish whether protein-bound ruthenium
is completely inactive or whether it may serve as a "reservoir" for the drug. A preliminary study of ours
demonstrated that adducts of Keppler compounds with transferrin conserve some biological activity in vitro
[21].
On the other hand the reported results provide evidence that ruthenium(III) complexes generally
exhibit a good ability to bind proteins; indeed all the investigated ruthenium(III) drugs bind proteins much
stronger than DNA [22]. This finding suggests that the important biological effects of antitumor
ruthenium(III) complexes might be linked to direct damage of some specific and crucial protein rather than to
DNA modifications. Further studies are needed to elucidate this critical issue.
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